Il trattamento integrato della carcinosi peritoneale

Translated title of the contribution: Integrated treatment of peritoneal carcinomatosis

F. Cavaliere, F. Di Filippo, S. Consolo, G. Cairella, M. Cosimelli, L. Di Lauro, A. Callopoli, C. Botti, M. Anza, P. Di Angelo, S. Giunta, L. Laurenzi, R. Cavaliere

Research output: Contribution to journalArticle

Abstract

Background. The transparietal diffusion of low-aggressive endoabdominal malignancy may develop into a massive peritoneal carcinomatosis without hematogenic and lymphatic metastatization. The lack of infiltration attitude lead to the cancer 'redistribution' on the peritoneum as an effect of gravity, intestinal peristalsis and peritoneal fluid riabsorption. Traditional target has often been palliation while the surgical intent should be the complete tumor cytoreduction removing peritoneum 'en-bloc' with the neoplastic implants. Intraoperative hyperthermic-antiblastic perfusion provides a direct contact between the drug and microscopic residual disease when they are entirely exposed. In the experience of Sugarbaker on 64 patients affected by peritoneal carcinomatosis from primary colorectal malignancy, the association of peritonectomy and regional chemotherapy led to a 3 years survival of 37%. Methods. Personal experience is reported of 31 patients affected by extensive peritoneal carcinomatosis, mostly from ovarian and primary colorectal malignancy prospectively studied and with a median follow-up of 16 months. Programmed treatment was peritonectomy associated to hyperthermic-antiblastic perfusion with CDDP 25 mg/m2/Lt of perfusate and MMC 3.3 mg/m2/Lt minutes. After peritonectomy the patients spend the first postoperative day at the Intensive Care Unit. Results. After the learning curve, operative time and blood loss have decreased and no mortality has been recorded in the last 15 months, with a feasibility for the integrated treatment that actually is of 100%. Median time of recurrence is 16 months with a two-years survival of 59%. Conclusions. The integrated treatment is feasible and offers new chances of cure to patients not responsive to conventional treatments.

Original languageItalian
Pages (from-to)87-91
Number of pages5
JournalChirurgia
Volume12
Issue number2
Publication statusPublished - 1999

Fingerprint

Carcinoma
Peritoneum
Neoplasms
Perfusion
Therapeutics
Peristalsis
Learning Curve
Survival
Ascitic Fluid
Gravitation
Operative Time
Intensive Care Units
Recurrence
Drug Therapy
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery

Cite this

Cavaliere, F., Di Filippo, F., Consolo, S., Cairella, G., Cosimelli, M., Di Lauro, L., ... Cavaliere, R. (1999). Il trattamento integrato della carcinosi peritoneale. Chirurgia, 12(2), 87-91.

Il trattamento integrato della carcinosi peritoneale. / Cavaliere, F.; Di Filippo, F.; Consolo, S.; Cairella, G.; Cosimelli, M.; Di Lauro, L.; Callopoli, A.; Botti, C.; Anza, M.; Di Angelo, P.; Giunta, S.; Laurenzi, L.; Cavaliere, R.

In: Chirurgia, Vol. 12, No. 2, 1999, p. 87-91.

Research output: Contribution to journalArticle

Cavaliere, F, Di Filippo, F, Consolo, S, Cairella, G, Cosimelli, M, Di Lauro, L, Callopoli, A, Botti, C, Anza, M, Di Angelo, P, Giunta, S, Laurenzi, L & Cavaliere, R 1999, 'Il trattamento integrato della carcinosi peritoneale', Chirurgia, vol. 12, no. 2, pp. 87-91.
Cavaliere F, Di Filippo F, Consolo S, Cairella G, Cosimelli M, Di Lauro L et al. Il trattamento integrato della carcinosi peritoneale. Chirurgia. 1999;12(2):87-91.
Cavaliere, F. ; Di Filippo, F. ; Consolo, S. ; Cairella, G. ; Cosimelli, M. ; Di Lauro, L. ; Callopoli, A. ; Botti, C. ; Anza, M. ; Di Angelo, P. ; Giunta, S. ; Laurenzi, L. ; Cavaliere, R. / Il trattamento integrato della carcinosi peritoneale. In: Chirurgia. 1999 ; Vol. 12, No. 2. pp. 87-91.
@article{03d0e97cbd934ff09bdc709ee2401d01,
title = "Il trattamento integrato della carcinosi peritoneale",
abstract = "Background. The transparietal diffusion of low-aggressive endoabdominal malignancy may develop into a massive peritoneal carcinomatosis without hematogenic and lymphatic metastatization. The lack of infiltration attitude lead to the cancer 'redistribution' on the peritoneum as an effect of gravity, intestinal peristalsis and peritoneal fluid riabsorption. Traditional target has often been palliation while the surgical intent should be the complete tumor cytoreduction removing peritoneum 'en-bloc' with the neoplastic implants. Intraoperative hyperthermic-antiblastic perfusion provides a direct contact between the drug and microscopic residual disease when they are entirely exposed. In the experience of Sugarbaker on 64 patients affected by peritoneal carcinomatosis from primary colorectal malignancy, the association of peritonectomy and regional chemotherapy led to a 3 years survival of 37{\%}. Methods. Personal experience is reported of 31 patients affected by extensive peritoneal carcinomatosis, mostly from ovarian and primary colorectal malignancy prospectively studied and with a median follow-up of 16 months. Programmed treatment was peritonectomy associated to hyperthermic-antiblastic perfusion with CDDP 25 mg/m2/Lt of perfusate and MMC 3.3 mg/m2/Lt minutes. After peritonectomy the patients spend the first postoperative day at the Intensive Care Unit. Results. After the learning curve, operative time and blood loss have decreased and no mortality has been recorded in the last 15 months, with a feasibility for the integrated treatment that actually is of 100{\%}. Median time of recurrence is 16 months with a two-years survival of 59{\%}. Conclusions. The integrated treatment is feasible and offers new chances of cure to patients not responsive to conventional treatments.",
keywords = "Antineoplastic agents administration and dosage, Gastrointestinal neoplasms, Hyperthermia, induced, Ovarian neoplasms, Peritoneal neoplasms drug therapy, Peritoneal neoplasms secondary, Peritoneum surgery, Pseudamyxoma peritonei",
author = "F. Cavaliere and {Di Filippo}, F. and S. Consolo and G. Cairella and M. Cosimelli and {Di Lauro}, L. and A. Callopoli and C. Botti and M. Anza and {Di Angelo}, P. and S. Giunta and L. Laurenzi and R. Cavaliere",
year = "1999",
language = "Italian",
volume = "12",
pages = "87--91",
journal = "Chirurgia (Turin)",
issn = "0394-9508",
publisher = "Minerva Medica",
number = "2",

}

TY - JOUR

T1 - Il trattamento integrato della carcinosi peritoneale

AU - Cavaliere, F.

AU - Di Filippo, F.

AU - Consolo, S.

AU - Cairella, G.

AU - Cosimelli, M.

AU - Di Lauro, L.

AU - Callopoli, A.

AU - Botti, C.

AU - Anza, M.

AU - Di Angelo, P.

AU - Giunta, S.

AU - Laurenzi, L.

AU - Cavaliere, R.

PY - 1999

Y1 - 1999

N2 - Background. The transparietal diffusion of low-aggressive endoabdominal malignancy may develop into a massive peritoneal carcinomatosis without hematogenic and lymphatic metastatization. The lack of infiltration attitude lead to the cancer 'redistribution' on the peritoneum as an effect of gravity, intestinal peristalsis and peritoneal fluid riabsorption. Traditional target has often been palliation while the surgical intent should be the complete tumor cytoreduction removing peritoneum 'en-bloc' with the neoplastic implants. Intraoperative hyperthermic-antiblastic perfusion provides a direct contact between the drug and microscopic residual disease when they are entirely exposed. In the experience of Sugarbaker on 64 patients affected by peritoneal carcinomatosis from primary colorectal malignancy, the association of peritonectomy and regional chemotherapy led to a 3 years survival of 37%. Methods. Personal experience is reported of 31 patients affected by extensive peritoneal carcinomatosis, mostly from ovarian and primary colorectal malignancy prospectively studied and with a median follow-up of 16 months. Programmed treatment was peritonectomy associated to hyperthermic-antiblastic perfusion with CDDP 25 mg/m2/Lt of perfusate and MMC 3.3 mg/m2/Lt minutes. After peritonectomy the patients spend the first postoperative day at the Intensive Care Unit. Results. After the learning curve, operative time and blood loss have decreased and no mortality has been recorded in the last 15 months, with a feasibility for the integrated treatment that actually is of 100%. Median time of recurrence is 16 months with a two-years survival of 59%. Conclusions. The integrated treatment is feasible and offers new chances of cure to patients not responsive to conventional treatments.

AB - Background. The transparietal diffusion of low-aggressive endoabdominal malignancy may develop into a massive peritoneal carcinomatosis without hematogenic and lymphatic metastatization. The lack of infiltration attitude lead to the cancer 'redistribution' on the peritoneum as an effect of gravity, intestinal peristalsis and peritoneal fluid riabsorption. Traditional target has often been palliation while the surgical intent should be the complete tumor cytoreduction removing peritoneum 'en-bloc' with the neoplastic implants. Intraoperative hyperthermic-antiblastic perfusion provides a direct contact between the drug and microscopic residual disease when they are entirely exposed. In the experience of Sugarbaker on 64 patients affected by peritoneal carcinomatosis from primary colorectal malignancy, the association of peritonectomy and regional chemotherapy led to a 3 years survival of 37%. Methods. Personal experience is reported of 31 patients affected by extensive peritoneal carcinomatosis, mostly from ovarian and primary colorectal malignancy prospectively studied and with a median follow-up of 16 months. Programmed treatment was peritonectomy associated to hyperthermic-antiblastic perfusion with CDDP 25 mg/m2/Lt of perfusate and MMC 3.3 mg/m2/Lt minutes. After peritonectomy the patients spend the first postoperative day at the Intensive Care Unit. Results. After the learning curve, operative time and blood loss have decreased and no mortality has been recorded in the last 15 months, with a feasibility for the integrated treatment that actually is of 100%. Median time of recurrence is 16 months with a two-years survival of 59%. Conclusions. The integrated treatment is feasible and offers new chances of cure to patients not responsive to conventional treatments.

KW - Antineoplastic agents administration and dosage

KW - Gastrointestinal neoplasms

KW - Hyperthermia, induced

KW - Ovarian neoplasms

KW - Peritoneal neoplasms drug therapy

KW - Peritoneal neoplasms secondary

KW - Peritoneum surgery

KW - Pseudamyxoma peritonei

UR - http://www.scopus.com/inward/record.url?scp=0032834459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032834459&partnerID=8YFLogxK

M3 - Articolo

VL - 12

SP - 87

EP - 91

JO - Chirurgia (Turin)

JF - Chirurgia (Turin)

SN - 0394-9508

IS - 2

ER -